AJMC Contributor

A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

The case shows how such cardiac involvement can mimic neurologic disease and demand complex, multidisciplinary management.

Researchers have developed a machine learning model that reliably predicts pulmonary hypertension (PH) risk in patients with chronic kidney disease (CKD).

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Synovial sarcoma—a rare, aggressive soft tissue cancer—can present as a painless hand swelling that mimics a harmless lesion, underscoring the need for early recognition and improved diagnostic access in low-resource settings.

CD45 + C1q + CCR8+ cells were found to be a novel immune-cell subset associated with kidney disease severity and progression risk.

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

Researchers developed a first-of-its-kind panel to track receptor expression and predict therapy response.

The study highlighted pain, fatigue, and functional status as key early warning signs.

Emotional well-being and social engagement significantly impact quality of life for patients with soft tissue sarcoma post-surgery.

Weight loss medications show promise in improving liver health for those with chronic liver conditions, a review found.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

Four autophagy-related variants in CDKN2A and BCL2 may increase susceptibility to chronic lymphocytic leukemia (CLL).

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

As oncology continues to move more toward precision medicine, tools like EVOFLUx may offer a more personalized roadmap from diagnosis to treatment.

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting.

This case highlights the diagnostic complexity and clinical management challenges of dual hematologic malignancies.

Ruxolitinib cream 15 mg/g provided rapid, meaningful repigmentation and improved quality of life for adults with nonsegmental vitiligo.

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

While observational studies have previously pointed to an association, being able to identify causation has been difficult due to overlapping risk factors and confounding variables.

Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.